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Abstract 
Background:  To study the utility of oral 
probiotics for preventing necrotizing enterocolitis 
(NEC) in low birth weight infants  
Methods:  In this randomized controlled study 
preterm infants, weighing less than 1500 grams and 
who were fit to receive enteral feeds (Stable vitals, 
soft abdomen with normal bowel sounds and no 
nasogastric aspirate) were included. Infants  were 
randomly assigned to two groups. Intervention 
group (Group A) was started on oral 
supplementation of probiotics(Mixture of 
Lactobacillus, Bifidobacterium and Streptococcus 
thermophilus in a dose of 109 CFU/day given in two 
divided doses)dissolved in breast milk twice a day 
till the complete enteral feed was established which 
was considered the end of study.  The control group 
(Group B) was only given breast milk.  The amount 
of feeding was increased slowly as per tolerance, 
with increments of no more than 20 ml/kg per day 
per feeding. Feeding was stopped in case of any sign 
of feeding intolerance. For quantitative variables 
(Gestational age, Birth weight) mean and standard 
deviation (SD) was calculated. For comparison of 
qualitative variables i.e. NEC in two groups, Chi 
square test was used. P value <0.05 was considered 
statistically significant. 
Results: Frequency of necrotizing enterocolitis in 
the study group was 10.95 % (7 cases) versus  23.28% 
(18cases) in control group 
Conclusion: The frequency of NEC in probiotics 
group is significantly less than those not given 
probiotics (P=0.04). 
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Introduction 
   Necrotising enterocolitis (NEC) is a common 
gastrointestinal emergency in neonatal age group, 
affecting 1–3% of total neonatal intensive care unit 
(NICU) admissions.1Infants with NEC  in NICU have a 
significantly high mortality rate ranging from 12-30%.2 
Higher fatality rates are associated with decreasing 
birth weight and gestational age.3 The patho-
physiology of necrotising enterocolitis is not yet 
completely understood.  High risk in preterm babies is 
explained by developmental immaturity of 
gastrointestinal motility, digestive ability, circulatory 
regulation, intestinal barrier function, and immune 
defence mechanisms. Other potential contributing 
factors include hypoxic-ischemic injury, feeding with 
formula milk, and colonisation by pathological 
bacteria.4Treatment is challenging with both medical 
and surgical options, hence leading to high short term 
as well as long term morbidity.5,6 
   With the improving early survival of preterm low 
birth weight babies the high risk population is 
continuously increasing, an effective preventive 
strategy for NEC is needed. Use of antenatal 
corticosteroids is a logical strategy to increase 
maturation of the fetus if preterm delivery is 
expected.5Exclusive feeding with breast milk, early 
initiation of trophic feeds and careful slow 
advancement of oral intake are being used while the 
use of oral antibacterials, antioxidants, 
supplementation of arginine and epidermal growth 
factor have been studied with no promising outcome. 
Recent studies have shown a promising role of 
prophylactic use of probiotics in prevention of NEC.5 
   Probiotics are defined as oral supplement or a food 
product that contains a sufficient number of viable 
microorganisms to alter the microflora of the host and 
has the potential for beneficial health effects.8 
Preventive role of probiotics for NEC has been widely 
studied in international literature.9-15 but local research 
on this topic is very scarce.  
 
Patients and Methods  
     This randomized controlled study was conducted in 
Neonatal Intensive Care Unit of Pakistan Ordinance 
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Factory Hospital, Wah Cantt, from November 2010 to 
December 2011 .Sample size was calculated by WHO 
sample size calculator by taking level of significance 
5%, power of test 90%,anticipated population 
proportion P1 =  16%,12 anticipated population 
proportion P212=4%. Sample size (n) calculated was 73 
in each group.Preterm infants weighing less than 1500 
grams and who were fit to receive enteral feeds (Stable 
vitals, soft abdomen with normal bowel sounds and no 
nasogastric aspirate) were eligible for inclusion in the 
study. A detailed clinical evaluation was done before 
enrolment and babies with confounding variables like 
birth asphyxia, chromosomal anomalies or congenital 
malformations, maternal pre-eclampsia and prolonged 
rupture of membranes were excluded. Informed 
consent was obtained from parents of babies in the 
final study cohort.  
      Participants were randomly assigned to two 
groups. Intervention group (Group A) was started on 
oral supplementation of probiotics(Mixture of 
Lactobacillus, Bifidobacterium and Streptococcus 
thermophilus in a dose of 109 CFU/day given in two 
divided doses)dissolved in breast milk twice a day till 
the complete enteral feed was established which was 
considered the end of study. The medication was 
administered by a staff nurse trained in feeding 
neonates. The control group (Group B) was only given 
breast milk. 
     Feeding protocol was according to institutional 
protocol and was same for infants in both groups. 
The amount of feeding was increased slowly as per 
tolerance, with increments of no more than 20 ml/kg 
per day per feeding. Feeding was stopped in case of 
any sign of feeding intolerance. Feeding intolerance 
was defined as the presence of gastric aspirate more 
than 50% of the previous feed volume on two 
consecutive occasions with abdominal 
distension.Main outcome i.e. NEC was diagnosed 
according to modified Bell criteria.17 To control bias 
the diagnosis was made by the registrar of NICU and 
confirmed by neonatologist.  Both were unaware of 
group assignment of the children. Then the standard 
treatment was initiated as per hospital protocol.For 
quantitative variables (Gestational age, Birth weight) 
mean and standard deviation (SD) was calculated. 
For qualitative variables (NEC, gender) frequencies 
were measured. For comparison of qualitative 
variables i.e. NEC in two groups, chi square test was 
used. P value <0.05 was considered statistically 
significant. 
   
Results 
A total of 146 patients were included in study, i.e.73 in 
intervention group and 73 in control group. . There 
were 45.2% males and 54.8% females among 
intervention group (Group A) whereas 57.5% males 
and 42.5% females among controls (Group B). Mean 
birth weight of all patients was 1.24 kilograms with the 
minimum of 0.8kg and maximum weight of 1.48 kg. 
Mean birth weight in group A was 1.2527 (SD + 
0.1292) while in group B this was 1.2739 kilograms (SD 
+ 0.1397).Mean gestational age for patients was32.046 
weeks with a standard deviation of 2.175, a minimum 
of 27.3 weeks and maximum of 36.3 weeks. Mean 
gestational age in weeks in group A is 32.027(SD 
+2.244) vs. 32.064 in group B (SD +2.119).Patients were 
enrolled in the study at a mean age of 4.91 days with 
the youngest patient at day 2 and eldest included at 
day 10 of life (Table 1).Primary outcome was 
measured in term of frequency of NEC in both groups. 
Only 8 out of 73 patients (10.95%) in the group A 
(intervention group) developed NEC, whereas 17 out 
of 73 patients (23.28%) in group B (control group) had 
this outcome(Table 2). Cumulative frequency of NEC 
in our study was 34.23%. The frequency of NEC in 
study group was significantly less than that in control 
group (p=0.04).  
 
Table 1. Demographic Details and study  
outcome in both groups 
Group GroupA (n=73) Group B (n=73) 
Weight in 
kilograms(mean) 
1.2527 1.2739 
Gestational age 
in weeks(Mean) 
32.027 32.064 
Gender(n) 
Male 33 
Female40 
Male 42   
Female31 
 
Table 2.Necrotizing Enterocolitis in two groups. 
Group Necrotizing Enterocolitis 
Group A (n=73) 10.95% (n=8) 
GroupB (n=73) 1. (n=17) 
p-value = 0.04 
 
Discussion 
    NEC is a disease familiar to all clinicians who deal 
with very low birth weight (VLBW) babies, and is also 
considered a disease of medical progress, because of  
routine use of antenatal steroids and prophylactic 
surfactant therapy for Respiratory Distress Syndrome, 
resulting in increased survival of preterm  
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infants.18There is a well-known inverse relationship 
between the incidence of NEC and gestational age at 
birth, hence the extremely premature and extremely 
low birth weight babies carry the highest risk for 
developing NEC.19 
    Described almost a century ago, this disease is still 
an enigma. Pathogenesis is still unproven; treatment is 
difficult and inadequate. Prevention strategies have 
not yet been agreed. The disease is especially poignant 
because it mainly affects premature infants who 
survive the early complications of prematurity but 
then face this lethal disease with high morbidity and 
mortality.2 
   This randomized controlled trial was done to 
demonstrate the preventive effect of oral proboitics on 
the frequency of NEC  in preterm infants weighing 
<1500 grams. This was hypothesized that these agents, 
when given in proper dosage, can result in significant 
reduction in frequency of NEC and the results 
supported this hypothesis. 
    NEC affects newborn, particularly low birth weight 
and premature babies. Other risk factors for NEC 
include  umbilical artery or vein catheterization, 
congenital heart diseases, exchange transfusions, 
aggressive enteral feeding, hyperosmolar formulas, 
indomethacin use and prolonged rupture of 
membranes.20Most of these factors were among the 
exclusion criteria in our study thus minimizing 
confounding. As it was a randomized trial, other risk 
factors were randomly distributed hence not affecting 
the outcome of study. 
  The two principal kinds of probiotic bacteria are 
members of the genera Lactobacillus and 
Bifidobacterium, which are present in the normal gut 
flora of healthy, breastfed, term neonates with 
significant dominance of Bifidobacterium over 
Lactobacillus.21,22 
   On the contrary, these very organisms are seen to be 
found in only <5% of extremely low birth weight 
infants within the first month of life.23 It suggests  that 
low colonization of Bifidobacterium and Lactobacillus 
in VLBW infants may serve as a predisposing factor in 
microbial infection, which is proposed basic pathology 
in NEC.So the probiotic supplementation can optimize 
the internal microbiological environment of gut and 
can prevent NEC in high risk patients. 
     Vast research has been done employing the use of 
same or similar agents for prevention of NEC. 
Different preparations and dosage regimens have been 
used to examine different primary and secondary 
outcomes, but for the same ultimate goal i.e. to reduce 
the mortality and morbidity associated with NEC 
(Table 3&4). 
Most important variables related to outcome are 
gestational age and weight. In our study the infants 
recruited were <37 weeks of gestation and weighing 
<1500 grams, which definitely includes some small for 
gestational age infants.  When compared to above 
mentioned studies, mean gestational age in present 
study is more, this is because of poor survival of  more 
preterm infants from immediate complications of 
prematurity, like RDS and intraventricular bleeding 
etc., where infants expire before they are fit to get oral 
feeds. 
 
Table 3. Demographic details of patients 
(Comparison of current study with similar 
international trials) 
Source 
Patients  
included 
Mean gestation 
(weeks) Probiotic 
Agent/s 
Mean Weight 
(grams) Primary  
outcome Study 
group 
Control 
group 
Study 
group 
Control 
group 
Kitajima et 
al.9 
<1500 g 28.3 28.2 BB 1615 1644 
Gut 
colonization 
by BB 
Dani et 
al.10 
28-32wks 30.8 31.7 LB-GG 1.325 1.345 
UTI, sepsis, 
NEC 
Costalos et 
al.11 
<33weeks/  
<1500 
31.1 31.8 SB 1651 1644 
Gut function 
and stool 
Colonization 
Bin Nun et 
al.12 
<1500 g 29.8 29.3 BI,ST,BBB 1152 1111 NEC 
Lin et al.13 <1500 g 28.5 28.2 LB-A,BI 1104 1071 
NEC or 
death 
Lin et al.14 
<34wk, 
<1500gms 
---- ----- BBB,LB-A 1028.9 1077.3 
NEC or 
death 
Samanta et 
al.15 
<34wk, 
<1500gms 
s 
30.12 30.14 
BBB,BB-
L,BI,LB-A 
 
1172 1210 
NEC, TFF, 
 sepsis, 
death, and 
hospital stay 
Rougé et 
al.16 
<32wk, 
<1500gms 
28.1 28.1 
BB-LG,LB 
GG 
1115 1057 
Enteral feed  
intake at 
CURRENT 
STUDY 
<37wk, 
<1500gms 
32.5 32.1 BB,LB,ST 1260 1270 NEC 
GA indicates gestational age; BB, Bifidobacterium breve; LB 
GG, Lactobacillus GG; SB, Saccharomyces boulardii; BI, 
Bifidobacteriam infantis; ST, Streptococcus thermophilus; 
BBB, Bifidobacterium bifidus; LB-A, Lactobacillus 
acidophilus; LB-C, Lactobacillus casei; BB-L, 
Bifidobacterium lactis; BB-LG, Bifidobacterium longum; UTI, 
urinary tract infection. 
 
Table 4. NEC (frequency and/ or severity in 
comparison with international trials) 
Source 
NEC (frequency and /or severity)  
Study Group Control Group P-value 
Kitajima et al.9 4% 16.4% >0.05 
Dani et al.10 1.4% (NEC > stage 2) 2.8% - 
Costalos et al.11 9.8% 16% 0.5 
Bin Nun et al.12 4% 16.4% 0.03 
Lin et al.13 1.1% (NEC > stage 2) 5.3% 0.04 
Lin et al.14 1.8% (NEC > stage 2) 6.45% 0.02 
Samanta et al.15 1.1% (NEC  stage 2 or 3) 15.8% 0.04 
PRESENT 
STUDY 
10.95% (NEC any stage) 23.28% 0.04 
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     Mean weight was also found to be greater  in 
comparison with past trials but this is not a marked 
difference as the weight criteria for inclusion in 
present study was in accordance to other trials. 
   As was demonstrated by international trials this 
product is safe and possibilities of invasive sepsis by 
the probiotic agent is minimal, so no cultures were 
carried out on study subjects especially for this 
purpose.The results were encouraging with significant 
reduction of frequency. 
    A higher frequency of NEC in controls as well as the 
treatment group has been noted in our experience as 
compared to other similar studies. This higher 
background incidence can again be caused by higher 
infection rates, compromised hygiene measures, 
overcrowded NICU, lack of staffing for nursing care 
and difference of local feeding protocol 
   In contrast to the several other trials, where formula 
and donor milk were also given, all the babies in our 
study were given mother’s milk, which has a 
preventive effect itself, and presumably this frequency 
could be even more if other feeds were also used.  
 
Conclusion 
1. Probiotics in the form of Bifidobacterium, 
Lactobacillus and Streptococcus, fed orally to very 
low birth weight preterm infants at the start of 
enteral nutrition reduce the incidence of 
necrotizing enterocolitis. 
2. Long term follow up studies can further  enlighten 
the role of probiotics in preventing neonatal 
enyterocolitis by giving credence to long term 
complications and mortality.  
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